{"id":462,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"survodutide-synchronize-1-2026-phase-3-data","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/survodutide-synchronize-1-2026-phase-3-data\/","title":{"rendered":"Survodutide dans SYNCHRONIZE-1\u00a0:\u00a0la phase 2026 Les nombres 3 en contexte"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">SYNCHRONIZE-1 est le plus grand essai publi\u00e9 \u00e0 ce jour sur l\u2019ob\u00e9sit\u00e9 survodutide. Les preuves utiles r\u00e9sident dans le d\u00e9nominateur complet, l\u2019estimation, la r\u00e9ponse au placebo et le profil des \u00e9v\u00e9nements ind\u00e9sirables, et non dans un seul pourcentage global.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Ce que montre le dossier<\/h2><ul class=\"wp-block-list\"><li>L\u2019essai a randomis\u00e9 des adultes 725 souffrant d\u2019ob\u00e9sit\u00e9 et non diab\u00e9tiques.<\/li><li>\u00c0 la semaine 76, la variation de poids moyenne \u00e9tait de \u221212.2% et \u221213.0% dans les deux groupes survodutide versus \u22125.4% avec le placebo.<\/li><li>Des \u00e9v\u00e9nements ind\u00e9sirables gastro-intestinaux sont survenus chez les participants 80.9% et 89.7% au survodutide versus 47.9% avec le placebo.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1536\" height=\"1024\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828.png\" alt=\"Un scientifique examine les donn\u00e9es d\u2019essais m\u00e9taboliques et deux voies de signalisation des r\u00e9cepteurs\" class=\"wp-image-457\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828.png 1536w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-300x200.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-1024x683.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-768x512.png 768w\" sizes=\"auto, (max-width: 1536px) 100vw, 1536px\" \/><figcaption class=\"wp-element-caption\">Illustration \u00e9ditoriale originale du contexte de recherche. Il ne s'agit pas d'une figure d'\u00e9tude, d'une image de patient, d'une photographie du produit fourni ou d'une repr\u00e9sentation du mat\u00e9riel d'essai.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">Dossier d'\u00e9tudes<\/h2><p class=\"wp-block-paragraph\">L'estimation du sch\u00e9ma th\u00e9rapeutique a rapport\u00e9 des changements moyens de \u221212.2% (95% CI, \u221213.6 \u00e0 \u221210.8) et \u221213.0% (95% CI, \u221214.4 \u00e0 \u221211.6), par rapport \u00e0 \u22125.4% (95% CI, \u22126.9 \u00e0 \u22124.0) pour le placebo. Les deux comparaisons actives \u00e9taient statistiquement significatives.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Conception<\/strong><span>Essai de phase 3 randomis\u00e9, en double aveugle et contr\u00f4l\u00e9 par placebo<\/span><\/div><div class=\"pim-evidence-row\"><strong>Participants<\/strong><span>725; \u00e2ge moyen 47.1 ans\u00a0; moyenne BMI 37.9<\/span><\/div><div class=\"pim-evidence-row\"><strong>R\u00e9sultat semaine-76<\/strong><span>\u221212.2%, \u221213.0% et \u22125.4% changement de poids moyen<\/span><\/div><div class=\"pim-evidence-row\"><strong>Au moins r\u00e9duction de 5%<\/strong><span>72.6%, 71.9% et 46.3%<\/span><\/div><div class=\"pim-evidence-row\"><strong>D\u00e9c\u00e8s<\/strong><span>Aucun rapport\u00e9 dans l'essai publi\u00e9<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">R\u00e9sultats en contexte<\/h2><p class=\"wp-block-paragraph\">Le crit\u00e8re d\u2019\u00e9valuation des r\u00e9pondeurs \u22655% va dans la m\u00eame direction, mais le groupe placebo a \u00e9galement eu une r\u00e9ponse substantielle. Cela est important car tous les groupes ont particip\u00e9 \u00e0 un essai contr\u00f4l\u00e9 plut\u00f4t qu\u2019\u00e0 une comparaison sans intervention.<\/p><p class=\"wp-block-paragraph\">Le journal qualifie le survodutide d\u2019investigation. Il n\u2019\u00e9tablit pas l\u2019interchangeabilit\u00e9 entre la formulation d\u2019essai et un mat\u00e9riel de catalogue provenant de sources ind\u00e9pendantes.<\/p><h2 class=\"wp-block-heading\">Ce \u00e0 quoi cette \u00e9tude ne peut pas r\u00e9pondre<\/h2><p class=\"wp-block-paragraph\">Les participants n\u2019\u00e9taient pas diab\u00e9tiques, le r\u00e9sultat ne doit donc pas \u00eatre g\u00e9n\u00e9ralis\u00e9 \u00e0 toutes les populations m\u00e9taboliques.<\/p><p class=\"wp-block-paragraph\">L'article 3 en une seule phase ne peut pas r\u00e9pondre aux questions sur l'utilisation \u00e0 long terme apr\u00e8s l'approbation, les \u00e9v\u00e9nements rares ou un lot de recherche sans rapport.<\/p>","protected":false},"excerpt":{"rendered":"<p>SYNCHRONIZE-1 est le plus grand essai publi\u00e9 \u00e0 ce jour sur l\u2019ob\u00e9sit\u00e9 survodutide. Les preuves utiles r\u00e9sident dans le d\u00e9nominateur complet, l\u2019estimation, la r\u00e9ponse au placebo et le profil des \u00e9v\u00e9nements ind\u00e9sirables, et non dans un seul pourcentage global.<\/p>","protected":false},"author":1,"featured_media":627,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"365","pim_article_type":"Published study case","pim_evidence_level":"Randomized phase 3 human trial; investigational intervention","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Survodutide Once Weekly for Adults with Obesity \u2014 SYNCHRONIZE-1\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42253238\/\",\"note\":\"2026 phase 3 primary record; PMID 42253238.\"},{\"title\":\"Survodutide phase 2 obesity trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38330987\/\",\"note\":\"Dose-ranging clinical context; PMID 38330987.\"},{\"title\":\"ClinicalTrials.gov NCT06066515\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT06066515\",\"note\":\"Registry record for SYNCHRONIZE-1.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context - NHD<\/title>\n<meta name=\"description\" content=\"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/survodutide-synchronize-1-2026-phase-3-data\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context\" \/>\n<meta property=\"og:description\" content=\"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/survodutide-synchronize-1-2026-phase-3-data\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\"},\"wordCount\":248,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\",\"name\":\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Survodutide dans SYNCHRONIZE-1\u00a0:\u00a0les num\u00e9ros 3 de la phase 2026 en contexte - NHD","description":"SYNCHRONIZE-1 est le plus grand essai publi\u00e9 \u00e0 ce jour sur l\u2019ob\u00e9sit\u00e9 survodutide. Les preuves utiles r\u00e9sident dans le d\u00e9nominateur complet, l\u2019estimation, la r\u00e9ponse placebo et\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/survodutide-synchronize-1-2026-phase-3-data\/","og_locale":"fr_FR","og_type":"article","og_title":"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context","og_description":"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026","og_url":"https:\/\/nhdbio.com\/fr\/survodutide-synchronize-1-2026-phase-3-data\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"},"wordCount":248,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","articleSection":["Published Study Reviews"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/","url":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/","name":"Survodutide dans SYNCHRONIZE-1\u00a0:\u00a0les num\u00e9ros 3 de la phase 2026 en contexte - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"SYNCHRONIZE-1 est le plus grand essai publi\u00e9 \u00e0 ce jour sur l\u2019ob\u00e9sit\u00e9 survodutide. Les preuves utiles r\u00e9sident dans le d\u00e9nominateur complet, l\u2019estimation, la r\u00e9ponse placebo et\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=462"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/462\/revisions"}],"predecessor-version":[{"id":514,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/462\/revisions\/514"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/627"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}